Six Humira competitors are poised to break through the patent thicket in 2023.
With over $16 billion in sales in 2020, the biologic drug Humira (adalimumab) remains far and away the top-selling drug by dollars in the United States. A “patent thicket” of over 100 patents has thwarted competitor drugs from coming to market. But now, at least six Humira biosimilars will finally enter the market in 2023.
In this infographic, we highlight actions you can take now to develop and implement strategies that will lead to higher adoption rates of Humira biosimilars.
Springbuk is the health data analytics solution that equips employers and benefits advisors with the deep, immediate insights they need to sharpen strategies, improve health, and contain costs.
Request a demo
